Gamma-Cyclodextrin Oligomers for Protein Aggregation Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for proteinopathies, such as Alzheimer's and Parkinson's diseases, are inadequate in preventing protein aggregation, reducing cytotoxicity, and alleviating inflammation, which contribute to disease progression and neural function loss.
Innovation Solution
Administration of a therapeutically effective amount of a pharmaceutical composition comprising gamma-cyclodextrin oligomers to prevent or reduce protein aggregation, deposition, and inflammation, thereby alleviating cytotoxicity and neural function decline in individuals with or at risk of proteinopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for proteinopathies, then disease management is maintained, but protein aggregation prevention and cytotoxicity reduction are inadequate
Solution Approach 1:
The patent uses cyclodextrin oligomers as intermediary substances that bind to hydrophobic regions of misfolded proteins, preventing their aggregation. The cyclodextrin structure acts as a mediator between the problematic protein aggregates and the cellular environment, sequestering the hydrophobic portions and preventing toxic interactions while maintaining solubility and reducing cytotoxicity.
Solution Approach 2:
The patent changes the physical-chemical parameters of the protein aggregates by introducing cyclodextrin oligomers that alter the hydrophobicity, solubility, and aggregation state of the proteins. This parameter change transforms the problematic hydrophobic aggregates into soluble, non-toxic complexes that can be cleared by cellular mechanisms.
2Object-affected harmful factors
If protein aggregation is prevented using conventional methods, then some aggregation is reduced, but cytotoxicity and inflammation are not sufficiently alleviated
Solution Approach 1:
The patent converts the harmful hydrophobic regions of misfolded proteins into beneficial interactions by having cyclodextrin oligomers bind to these regions. The previously harmful hydrophobic interactions that drove aggregation are transformed into beneficial soluble complexes that reduce cytotoxicity and can be cleared by cellular processes, turning the problematic hydrophobicity into a therapeutic opportunity.
Solution Approach 2:
The cyclodextrin oligomers serve as intermediaries that reduce both protein aggregation and the resulting cytotoxicity. By binding to the hydrophobic regions, they prevent aggregation formation and simultaneously eliminate the cytotoxic effects, also reducing inflammation as a downstream benefit of preventing protein aggregate formation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The gamma-cyclodextrin oligomer composition effectively reduces protein aggregation by at least 10% and associated cytotoxicity and inflammation, slowing or reversing disease progression and neural function loss in proteinopathy patients.
Implementation Method 1
gamma-cyclodextrin oligomer composition... preventing or reducing protein (e.g., amyloid beta, alpha-synuclein, or tau) aggregation
Data Source
AI summary
Provided is a method of i) preventing or reducing protein aggregation, ii) reducing protein deposition, iii) reducing cytotoxicity induced by protein aggregation or deposition or deposition, or iv) alleviating or reducing inflammation induced by protein aggregation or deposition in an individual, wherein the method comprises administering a therapeutically effective amount of a pharmaceutical composition including a gamma-cyclodextrin oligomer to the individual, thereby preventing or reducing protein aggregation, reducing protein deposition, reducing cytotoxicity induced by protein aggregation or deposition, or alleviating or reducing inflammation induced by protein aggregation or deposition in the individual diagnosed with, suspected to have, or at risk of developing proteinopathy.